Sunshine Biopharma Inc.

false 0001402328 0001402328 2026-08-25 2026-08-25 0001402328 us-gaap:CommonStockMember 2026-08-25 2026-08-25 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2026-08-25 2026-08-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2026 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 20-5566275 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer ID No.) 333 Las Olas Way CU4 Suite 433 Fort Lauderdale , FL 33301 (Address of principal executive offices) (Zip Code) (954) 330-0684 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he will not be seeking or accepting reelection to the Board of Directors of the Company upon completion of his current term. Dr. Keller’s current term will expire at the Company’s next annual shareholder meeting. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 28, 2026 SUNSHINE BIOPHARMA INC. By: /s/ Dr. Steve N. Slilaty Name: Dr. Steve N. Slilaty, Chief Executive Officer 3